Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers
Inflammopharmacology · 2025-12 · 33 (12) · 7269-7314
DOI: 10.1007/s10787-025-02012-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 08.11.2025. Verfasst von Dlzar D Ghafoor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, University of Sulaimani, Kurdistan Regional Government, Qlyasan Street, Sulaymaniyah, 46001, Iraq. dlzar…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 351 Literaturangaben.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a complex, chronic neuroinflammatory and neurodegenerative disorder of the central nervous system. This comprehensive review synthesizes evidence to argue that the paramount challenge in MS is bridging the disconnect between anti-inflammatory therapies and ineffective neuroprotective strategies, necessitating a dual-target approach. The paper discusses the crucial roles of genetic predisposition, highlighting the HLA-DRB1*15:01 allele and other non-HLA loci, and environmental triggers, such as Epstein-Barr virus infection, vitamin D deficiency, and smoking. We detail the dysregulation of both T-cells (Th1 and Th17 subsets) and B-cells in the autoimmune attack on myelin, as well as the intricate mechanisms of neurodegeneration, axonal damage, and the challenges of remyelination. The review also incorporates emerging insights into the role of the gut microbiome and epigenetic modifications, underscoring the necessity of an integrative model to understand MS pathogenesis. Ultimately, this review provides a foundational understanding of converging biological drivers of MS. Therapeutically, currently approved disease-modifying therapies (DMTs)-including interferon-β, glatiramer acetate, oral S1P modulators, fumarates, teriflunomide, cladribine, natalizumab, and anti-CD20 monoclonals-reduce relapse frequency and MRI activity but do not eliminate disability progression, particularly in progressive MS. Acute relapses are treated with high-dose corticosteroids, with plasma exchange reserved for steroid-refractory cases. We therefore argue that future success requires integrated strategies that couple sustained control of peripheral inflammation with CNS-intrinsic neuroprotection and remyelination. Therapeutically, modern disease-modifying therapies (interferon-β, glatiramer acetate, oral S1P modulators, fumarates, teriflunomide, cladribine, natalizumab, anti-CD20 monoclonals including ocrelizumab, ofatumumab, and ublituximab) reduce relapse rates and MRI activity yet do not consistently prevent disability progression-particularly in non-active progressive MS. Acute relapses are treated with high-dose corticosteroids; plasma exchange is reserved for steroid-refractory attacks. These realities motivate mechanism-informed strategies that pair sustained immune control with CNS-intrinsic neuroprotection and remyelination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, College of Science, University of Sulaimani, Kurdistan Regional Government, Qlyasan Street, Sulaymaniyah, 46001, Iraq. dlzar.ghafoor@komar.edu.iq.
- Department of Medical Laboratory Sciences, Komar University of Science and Technology, Kurdistan Regional Government, Sulaymaniyah, 46001, Iraq. dlzar.ghafoor@komar.edu.iq.
- Department of Chemistry, College of Science, University of Sulaimani, Kurdistan Regional Government, Qlyasan Street, Sulaymaniyah, 46001, Iraq.
- Department of Biology, College of Science, University of Sulaimani, Kurdistan Regional Government, Qlyasan Street, Sulaymaniyah, 46001, Iraq.
- Department of Medical Laboratory Analysis, College of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah City, Kurdistan, Iraq.
- Department of Medical Laboratory Sciences, Majmaah University, 11952, Majmaah, Saudi Arabia.
Zitieren
APA
Ghafoor, D. D., Ahmad, D. O., Najmuldeen, H. H., Mohammed, S. J., Jalal, P. J., Mustafa, F. S., Alghofaili, F., Zangana, B. A., & Al-Bajalan, S. J. (2025). Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers. Inflammopharmacology, 33(12), 7269-7314. https://doi.org/10.1007/s10787-025-02012-5
Vancouver
Ghafoor DD, Ahmad DO, Najmuldeen HH, Mohammed SJ, Jalal PJ, Mustafa FS, et al. Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers. Inflammopharmacology. 2025;33(12):7269-7314. doi:10.1007/s10787-025-02012-5
BibTeX
@article{Ghafoor2025,
author = {Ghafoor, Dlzar D and Ahmad, Dlshad O and Najmuldeen, Hastyar H and Mohammed, Sewara J and Jalal, Paywast J and Mustafa, Fryad S and Alghofaili, Fayez and Zangana, Bahashty A and Al-Bajalan, Sarwer J},
title = {Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {12},
pages = {7269--7314},
doi = {10.1007/s10787-025-02012-5}
}
EUVIMED